Literature DB >> 23213090

On the merits and limitations of whole-brain radiation therapy.

Atif J Khan, Adam P Dicker.   

Abstract

Mesh：

Year:  2012        PMID： 23213090     DOI： 10.1200/JCO.2012.46.0410

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  17 in total

Review 1.  Brain metastasis in lung cancer: Building a molecular and systems-level understanding to improve outcomes.

Authors:  Johnathan D Ebben; Ming You
Journal:  Int J Biochem Cell Biol       Date:  2016-07-27       Impact factor: 5.085

2.  Real-world analysis of clinicopathological characteristics, survival rates, and prognostic factors in patients with melanoma brain metastases in China.

Authors:  Yang Wang; Bin Lian; Lu Si; ZhiHong Chi; XiNan Sheng; Xuan Wang; LiLi Mao; BiXia Tang; SiMing Li; XieQiao Yan; Xue Bai; Li Zhou; ChuanLiang Cui; Jun Guo
Journal:  J Cancer Res Clin Oncol       Date:  2021-02-21       Impact factor: 4.553

3.  Prognostic stratification of brain metastases from hepatocellular carcinoma.

Authors:  Kyung Su Kim; Kyubo Kim; Eui Kyu Chie; Yoon Jun Kim; Jung Hwan Yoon; Hyo-Suk Lee; Sung W Ha
Journal:  J Neurooncol       Date:  2014-07-23       Impact factor: 4.130

4.  Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

Authors:  Sarah B Goldberg; Scott N Gettinger; Amit Mahajan; Anne C Chiang; Roy S Herbst; Mario Sznol; Apostolos John Tsiouris; Justine Cohen; Alexander Vortmeyer; Lucia Jilaveanu; James Yu; Upendra Hegde; Stephanie Speaker; Matthew Madura; Amanda Ralabate; Angel Rivera; Elin Rowen; Heather Gerrish; Xiaopan Yao; Veronica Chiang; Harriet M Kluger
Journal:  Lancet Oncol       Date:  2016-06-03       Impact factor: 41.316

5.  Multi-disciplinary management for patients with oligometastases to the brain: results of a 5 year cohort study.

Authors:  Jillian Maclean; Naomi Fersht; Mausam Singhera; Paul Mulholland; Orla McKee; Neil Kitchen; Susan C Short
Journal:  Radiat Oncol       Date:  2013-06-27       Impact factor: 3.481

6.  Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial.

Authors:  Michelle M Kim; Hemant Parmar; Yue Cao; Priyanka Pramanik; Matthew Schipper; James Hayman; Larry Junck; Aaron Mammoser; Jason Heth; Corey A Carter; Arnold Oronsky; Susan J Knox; Scott Caroen; Bryan Oronsky; Jan Scicinski; Theodore S Lawrence; Christopher D Lao
Journal:  Transl Oncol       Date:  2016-04       Impact factor: 4.243

Review 7.  The Emerging Role of Targeted Therapy and Immunotherapy in the Management of Brain Metastases in Non-Small Cell Lung Cancer.

Authors:  Annick Wong
Journal:  Front Oncol       Date:  2017-04-05       Impact factor: 6.244

8.  Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers.

Authors:  Steven Brem; Christina A Meyers; Gary Palmer; Margaret Booth-Jones; Surbhi Jain; Matthew G Ewend
Journal:  Cancer       Date:  2013-08-23       Impact factor: 6.860

9.  Surgical Cavity Constriction and Local Progression Between Resection and Adjuvant Radiosurgery for Brain Metastases.

Authors:  Jugal K Shah; Matthew B Potts; Penny K Sneed; Manish K Aghi; Michael W McDermott
Journal:  Cureus       Date:  2016-04-19

10.  Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.

Authors:  Dong-Wan Kim; Ranee Mehra; Daniel S W Tan; Enriqueta Felip; Laura Q M Chow; D Ross Camidge; Johan Vansteenkiste; Sunil Sharma; Tommaso De Pas; Gregory J Riely; Benjamin J Solomon; Jürgen Wolf; Michael Thomas; Martin Schuler; Geoffrey Liu; Armando Santoro; Santosh Sutradhar; Siyu Li; Tomasz Szczudlo; Alejandro Yovine; Alice T Shaw
Journal:  Lancet Oncol       Date:  2016-03-11       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.